The popular High Blood Pressure medicine Benicar (olmesartan medoxomil) is manufactured by the Daiichi Sankyo Corporation. U.S. doctors prescribe the drug for more than 11-million patients nationwide. Several years ago it was discovered that it took a couple of years for a nasty side-effect of the drug to materialize. That particular side effect on a patient’s gastro-intestinal tract is causing serious problems for some patients.
The problems specifically listed by the Multi-District Litigation (MDL) include intestinal damage, chronic diarrhea, malnourishment, severe weight loss, and a celiac-type symptom. This celiac like symptom usually ends up being properly diagnosed as “sprue-like entropy”, or villous atrophy. Both are serious problems for patients. In addition, the drug holds a “black box warning” denoting fetal toxicity.
This drug was originally approved by the FDA back in 2002. The Mayo Clinic originally contacted the FDA in 2012 after their studies into reported side-effects found a link between gastrointestinal symptoms and the drug olmesartan medoxomil. This advisement caused the FDA to add a label warning to the drug.
If you wish to be included in a Multi District Lawsuit please contact email@example.com for further interviews and advisements.
*****A VITAL NOTE FROM THE PIRL TEAM: As we report on any medical product/medication case - NEVER STOP OR ALTER A MEDICAL PROGRAM OR COURSE OF MEDICATION WITHOUT CONSULTING YOUR(S) OR A PHYSICIAN.*****